

1 Nathan J. Kunz (AZ Bar No. 024819)  
2 Malvika A. Sinha (AZ Bar No. 038046)  
3 COPPERSMITH BROCKELMAN PLC  
4 2800 North Central Avenue, Suite 1900  
5 Phoenix, Arizona 85004  
6 Tel.: (602) 381-5472  
7 [nkunz@cblawyers.com](mailto:nkunz@cblawyers.com)  
8 [msinha@cblawyers.com](mailto:msinha@cblawyers.com)

9 Kevin P.B. Johnson (*pro hac vice forthcoming*)  
10 Victoria F. Maroulis (*pro hac vice forthcoming*)  
11 QUINN EMANUEL URQUHART & SULLIVAN, LLP  
12 555 Twin Dolphin Dr., 5th Floor  
13 Redwood Shores, CA 94065  
14 Tel.: (650) 801-5000  
15 [kevinjohnson@quinnemanuel.com](mailto:kevinjohnson@quinnemanuel.com)  
16 [victoriamaroulis@quinnemanuel.com](mailto:victoriamaroulis@quinnemanuel.com)

17 (*Additional counsel listed in signature line below*)

18 *Attorneys for Plaintiffs,*  
19 *JUUL Labs, Inc. and VMR Products LLC*

20  
21  
22  
23  
24  
25  
26  
**UNITED STATES DISTRICT COURT**  
**DISTRICT OF ARIZONA**

27 JUUL Labs, Inc. and VMR Products LLC ,  
28  
29 Plaintiffs,  
30  
31 v.  
32  
33 NJOY, LLC, NJOY Holdings, Inc., Altria  
34 Group, Inc., Altria Group Distribution  
35 Company, and Altria Client Services LLC,  
36 Defendants.

No.

**COMPLAINT FOR PATENT  
INFRINGEMENT**

**JURY TRIAL DEMAND**

1 **I. INTRODUCTION**

2 1. Plaintiffs JUUL Labs, Inc. and VMR Products LLC<sup>1</sup> (collectively “JLI” or  
3 “Plaintiffs”), by and through their undersigned counsel, respectfully file this civil action  
4 for infringement of U.S. Patent No. RE49,114, U.S. Patent No. 10,130,123, U.S. Patent  
5 No. 10,709,173, U.S. Patent No. 11,134,722, and U.S. Patent No. 11,606,981 (collectively  
6 the “Asserted Patents”) arising under the patent laws of the United States, 35 U.S.C. §§ 1  
7 *et seq.*

8 2. As discussed in Section II of this Complaint, JLI was founded in 2007 with  
9 the goal of developing a less harmful alternative to traditional combustible cigarettes. After  
10 years of effort across product design, engineering, and scientific research, and over a billion  
11 dollars invested domestically, JLI accomplished that goal by developing technology that  
12 revolutionized a category of vaporizing products known as electronic nicotine delivery  
13 system (“ENDS”) products. JLI is now a global leader in the ENDS industry, where it is  
14 known for numerous, meaningful technological advancements. JLI continues to invest  
15 heavily in innovation to sustain existing products and develop new ones. Unfortunately,  
16 JLI’s innovation and resulting success has bred numerous entities who unlawfully use JLI’s  
17 patented technology.

18 3. The defendants are NJOY, LLC and NJOY Holdings, Inc. (collectively  
19 “NJOY”); and Altria Group, Inc., Altria Group Distribution Company, and Altria Client  
20 Services LLC (collectively “Altria”) (all collectively “Defendants”).

21 4. This Complaint is based on Defendants’ unlawful infringement of the  
22 Asserted Patents, including one or more of at least the following claims:  
23  
24  
25

---

26 <sup>1</sup> VMR Products LLC is a wholly owned subsidiary of JUUL Labs, Inc.

<b>Asserted Patent</b>	<b>Claims Asserted Against Defendants (independent claims in bold)</b>
U.S. Patent No. RE49,114	<b>1</b> , 5-7, 29, 30, 36, <b>43, 44</b> , 76, 77, 80, 81, 86, 89, 93
U.S. Patent No. 10,130,123	<b>14</b> , 16, 18, <b>27</b> , 29, 31, 32
U.S. Patent No. 10,709,173	<b>1</b> , 2-4, 6-7, 15, 16, 18, 19, <b>20</b> , 21-25, 28, 30
U.S. Patent No. 11,134,722	<b>1</b> , 3, 5, 7-9, <b>10</b> , 11-14, <b>15</b> , 16-21
U.S. Patent No. 11,606,981	<b>1</b> , 2, 5, 6, 8, <b>9</b> , 10, 11, <b>13</b> , 14-16, <b>17</b> , 18

## II. PLAINTIFFS

5. JUUL Labs, Inc. is a privately held corporation organized and existing under the laws of the State of Delaware, with its principal place of business as of the date of the initiation of this proceeding at 1000 F Street NW, Washington, D.C. 20004.

6. VMR Products LLC is a privately held corporation organized and existing under the laws of the State of Florida, with its principal place of business as of the date of the initiation of this proceeding at 560 20th Street, San Francisco, California 94107. VMR Products LLC is a wholly owned subsidiary of JUUL Labs, Inc.

7. After years of research and over a billion dollars invested domestically, JLI has become one of the world's leading ENDS companies.

### A. JLI's History

8. JLI was founded and incorporated in 2007 with the goal of transitioning the world's billion adult smokers away from combustible cigarettes.<sup>2</sup> Use of combustible cigarettes remains the leading cause of preventable death in the world and cigarettes are widely acknowledged to kill up to or more than 50% of their long-time users.<sup>3</sup>

<sup>2</sup> As described more fully in the remaining paragraphs in this Section, JLI began as a company called "Ploom, Inc." Ploom, Inc. was later renamed to "PAX Labs, Inc.," and PAX Labs, Inc. was later renamed to "JUUL Labs, Inc."

<sup>3</sup> See *Tobacco: Key Facts*, World Health Organization (May 24, 2023), <https://www.who.int/news-room/fact-sheets/detail/tobacco> ("Tobacco kills up to half of its users.").

1           9.       When JLI was founded, the health hazards of smoking combustible cigarettes  
 2 were well understood. Smoking was and still is the number one cause of preventable death  
 3 in the United States. *See Health Risks of Smoking Tobacco*, American Cancer Society  
 4 (May 25, 2023), [https://www.cancer.org/cancer/cancer-causes/tobacco-and-cancer/health-](https://www.cancer.org/cancer/cancer-causes/tobacco-and-cancer/health-risks-of-smoking-tobacco.html)  
 5 [risks-of-smoking-tobacco.html](https://www.cancer.org/cancer/cancer-causes/tobacco-and-cancer/health-risks-of-smoking-tobacco.html). Smoking not only steals valuable years of life but also has  
 6 a significant economic cost. The Centers for Disease Control and Prevention estimates that  
 7 “[c]igarette smoking cost the United States more than \$600 billion in 2018,” including  
 8 “[m]ore than \$240 billion in healthcare spending, [n]early \$185 billion in lost productivity  
 9 from smoking-related illnesses and health conditions in lost productivity, [and] [n]early  
 10 \$180 billion in lost productivity from smoking-related premature death . . . .” *See Smoking*  
 11 *& Tobacco Use: Economic Trends in Tobacco*,” Centers for Disease Control and  
 12 Prevention (May 25, 2023),  
 13 [https://www.cdc.gov/tobacco/data\\_statistics/fact\\_sheets/economics/econ\\_facts/index.htm](https://www.cdc.gov/tobacco/data_statistics/fact_sheets/economics/econ_facts/index.htm).

14           10.       After studying Product Design in graduate school at Stanford University,  
 15 JLI’s founders, James Monsees and Adam Bowen, applied their knowledge of design and  
 16 engineering to the challenge of developing an alternative to combustible cigarettes through  
 17 ENDS products. Both smokers at the time, they experienced a lack of compelling  
 18 alternatives to smoking for adults who wanted to enjoy nicotine but wanted to move away  
 19 from traditional combustible cigarettes.

20           11.       ENDS technology represented a potential alternative for reducing the  
 21 exposure of adult smokers—and those around them—to the toxic compounds released by  
 22 use of combustible cigarettes. ENDS products deliver nicotine, but do so without burning  
 23 tobacco and are thus noncombustible tobacco products. Studies have shown that switching  
 24 from cigarettes to ENDS products can reduce exposure to certain toxic byproducts of  
 25 smoking traditional cigarettes by up to 95% or more. Former FDA Commissioner Scott  
 26 Gottlieb, M.D., explained that “it’s primarily the combustion, which releases thousands of

1 harmful constituents into the body at dangerous levels, that kills people.” See Statement  
 2 from FDA Commissioner Scott Gottlieb, M.D., FDA Newsroom (Sept. 11, 2018),  
 3 [https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-](https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-new-steps-address-epidemic-youth-e-cigarette-use)  
 4 [scott-gottlieb-md-new-steps-address-epidemic-youth-e-cigarette-use](https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-new-steps-address-epidemic-youth-e-cigarette-use).

5 12. While promising, initial ENDS products showed challenges to durably  
 6 switching the adult smoker’s consumption of combustible cigarettes. Several factors  
 7 contributed to low switching rates with early non-combustible devices, including poor  
 8 nicotine delivery, unreliability, poor device quality, form factor issues, complexity, and  
 9 maintenance required for some devices. Early generation “cig-a-like” products, typically  
 10 cylindrical in design like a cigarette, failed to break from traditional cigarette iconography,  
 11 often had poor nicotine delivery that failed to match the experience of consuming a  
 12 combustible cigarette, and were either not rechargeable or suffered from inconvenient  
 13 cartridge coupling mechanisms, inconsistent operation, etc. Tank systems, including  
 14 cartomizers and “mods,” were bulky, complicated, and impractical—requiring user  
 15 modifications and refilling with nicotine e-liquids.<sup>4</sup> Such cartomizers and mods were  
 16 difficult to use, troublesome to refill with e-liquid, leaky, bulky, and inconvenient.<sup>5</sup>

17 13. Most early alternatives, including early e-cigarettes, continued the  
 18 combustible cigarette iconography in that they were “either small and round, designed to

19  
 20 <sup>4</sup> See Jean-Francois Etter, *Electronic Cigarettes: A Survey of Users*, 10 BMC Pub. Health  
 21 231 (2010); see also Carla J. Berg, et. al., *Attitudes Toward E-Cigarettes, Reasons for*  
 22 *Initiating E-Cigarette Use and Changes in Smoking Behavior After Initiation: A Pilot*  
*Longitudinal Study of Regular Cigarette Smokers*, 4 Open J. Preventive Med. 789 (2014).

23 <sup>5</sup> See Neil McKeganey & Tiffany Dickson, *Why Don't More Smokers Switch to Using E-*  
 24 *Cigarettes: The Views of Confirmed Smokers*, 14 Int’l J. Env’tl. Res. Pub. Health 647  
 25 (2017); Amy McQueen, Stephanie Tower & Walton Sumner, *Interviews with “Vapers”:*  
 26 *Implications for Future Research with Electronic Cigarettes*, 13 Nicotine Tobacco Res.  
 860 (2011); Jean-Francois Etter & Chris Bullen, *Electronic Cigarette: Users Profile,*  
*Utilization, Satisfaction and Perceived Efficacy*, 106 Addiction 2017 (2011).

1 look and feel as much as possible like a cigarette,” or were inaccessible to many as they  
2 were “huge, assembled from many parts, and spectacularly complicated.” See David  
3 Pierce, *This Might Just Be the First Great ECIG*, Wired (Apr. 21, 2015),  
4 <https://www.wired.com/2015/04/pax-juul-ecig/>. During the course of their Master’s thesis  
5 project in product design, James and Adam developed prototypes of a non-combustible  
6 nicotine delivery system to address these shortcomings.

7       14. After graduate school, James and Adam started a company called Ploom, Inc.  
8 (“Ploom”) to continue developing and commercializing tobacco-alternative devices. The  
9 original Ploom device was a butane-powered vaporizer that heated solid tobacco material  
10 sufficiently to create a nicotine-containing inhalable aerosol while using a sufficiently low  
11 temperature to avoid igniting the tobacco material, a type of system referred to as “heat-  
12 not-burn.” The Ploom device included a button-actuated heater and removable  
13 mouthpiece. In 2015, Ploom changed its name to PAX Labs, Inc. (“Pax”). James and  
14 Adam, through Pax, continued to innovate new and better designs for non-combustible  
15 nicotine delivery products.

16       15. In 2015, Pax revolutionized the market for ENDS products with the release  
17 of its signature product, the JUUL electronic nicotine delivery system (the “JUUL  
18 System”). Through its many innovations in industrial design, technical engineering, and  
19 chemistry, the JUUL System disrupted the stagnant and failing category of non-  
20 combustible alternatives to combustible cigarettes. Adult smokers had experimented with  
21 predecessor e-cigarette and electronic smoking alternative products, going back at least to  
22 the 1980s. However, none of those products ever gained significant traction. JLI’s  
23 deliberate departure from early-generation technology changed that pattern, and the JUUL  
24 System’s arrival gave adult smokers the first viable alternative to traditional cigarettes.

25       16. On June 30, 2017, Pax was renamed JUUL Labs, Inc. JLI then spun off non-  
26 nicotine products (*i.e.*, not including the JUUL System), as well as related personnel and

1 resources, into a new, distinct corporate entity named Pax Labs (Deux), Inc., which was  
2 later renamed to Pax Labs, Inc. (“New Pax”). New Pax focuses on other vaporization fields  
3 that do not involve nicotine.

4 **B. The JUUL System**

5 17. The JUUL System is a closed, cartridge-based product that uses precision  
6 heating technology to aerosolize and deliver nicotine without combustion. It was designed  
7 to break away from the “round white stick” iconography associated with smoking and used  
8 a simple interface requiring no buttons, switches, or complex manipulation, coupled with  
9 an e-liquid formulation and carefully engineered internal architecture to deliver a  
10 combustible cigarette-like experience. The transformative design and operation of the  
11 JUUL System were unique advancements over previous, much less successful ENDS  
12 products that were difficult to use, unsatisfying, and/or inconsistent in their delivery of  
13 aerosolized nicotine. As a result of its ease of use and satisfying and reliable performance,  
14 the JUUL System quickly gained recognition among adult smokers. It has been and  
15 continues to be one of the best-selling ENDS products in the United States.

16 18. The JUUL System comprises three primary and proprietary components: (i)  
17 a device body containing a rechargeable battery, control circuitry, and a receptacle for a  
18 cartridge (“JUUL Device”); (ii) a non-refillable cartridge (branded as a “JUULpod”) that  
19 is specifically designed to be inserted into the cartridge receptacle on the device body, has  
20 a resistive heater-based atomizer, and is pre-filled with a proprietary nicotine e-liquid  
21 formulation; and (iii) a charger that is specifically designed for charging the device body.  
22 When a user inhales through the mouthpiece of a JUULpod that has been inserted into the  
23 cartridge receptacle of the JUUL Device body, the device rapidly heats to vaporize the  
24 nicotine e-liquid, which recondenses to generate an aerosol that is ultimately inhaled by  
25 the user.

19. By way of illustration, the JUUL System is generally shown in the renderings below:



JUUL Device



JUULpod



JUUL System

20. The JUUL System looks simple, yet distinctive. It employs a unique form factor that represents a stark departure from prior conventional thinking about ENDS product design and from contemporary industry norms, abandoning traditional cigarette designs altogether, including the cylindrical shape. Its innovative design distinguishes it from the “round white stick” iconography found in both traditional combustible cigarettes and from previous alternative e-cigarettes. JLI was immediately praised for “strong design savvy” and for creating a “beautiful” product. See David Pierce, *This Might Just Be the*



1 *First Great ECIG*, Wired (Apr. 21, 2015), <https://www.wired.com/2015/04/pax-juul-ecig/>;  
2 Tom Miller, *Pioneers: Adam Bowen and James Monsees*, Time Magazine (Sept. 16, 2019),  
3 [https://time.com/collection/100-most-influential-people-2019/5567701/adam-bowen-](https://time.com/collection/100-most-influential-people-2019/5567701/adam-bowen-james-monsees/)  
4 [james-monsees/](https://time.com/collection/100-most-influential-people-2019/5567701/adam-bowen-james-monsees/).

5 21. A JUULpod cartridge consists of two basic parts: a cartridge and a cap, which  
6 is removed from the cartridge prior to use. As shown in the example JUULpod renderings  
7 below, the JUULpod cartridge has an overall rectangular shape—a deliberate departure  
8 from the cylinder-shaped cartridges that came before it.



16 22. Moreover, looking at the JUULpod cartridge with the cap removed (as shown  
17 in the rendering below), more than one-half of the cartridge is light transmissive to allow  
18 a user to view the nicotine e-liquid remaining in the tank as well as other internal  
19 components. Older cartridge designs were typically opaque at the distal end, which  
20 connected to the device body, and were often made of metal.



23. The JUUL System has attained tremendous commercial success and acclaim, reportedly garnering around 60-70% of the overall tracked e-cigarette market in the U.S. in the years following its launch.

24. JLI has since further innovated and created the JUUL2 System. Like the JUUL System, the JUUL2 System is comprised of three primary and proprietary components: (i) a device body containing a rechargeable battery, control circuitry, and a receptacle for a cartridge; (ii) a non-refillable cartridge (branded as a "JUUL2 pod") that is specifically designed to be inserted into the cartridge receptacle on the device body, has a resistive heater-based atomizer, and is pre-filled with a proprietary nicotine e-liquid formulation; and (iii) a charger that is specifically designed for charging the device body. The JUUL 2 System is designed, developed, and assembled in the United States, and exported and sold outside of the United States

25. JLI is committed to providing quality products that perform consistently to JLI's specifications. JLI continues to invest in creating and maintaining strict manufacturing and quality standards for its products and relies on multiple safeguards, testing standards, and quality controls.

### 1 **III. DEFENDANTS**

2 26. On information and belief, NJOY, LLC is limited liability company  
 3 organized under the laws of Delaware, with its principal place of business located at 8825  
 4 N. 23rd Avenue, Suite 100, Phoenix, Arizona 85021. On information and belief, NJOY,  
 5 LLC was acquired by Altria Group, Inc. on June 1, 2023, and is now a wholly owned  
 6 subsidiary of Altria Group, Inc. See [https://investor.altria.com/press-releases/news-](https://investor.altria.com/press-releases/news-details/2023/Altria-Completes-Acquisition-of-NJOY-Holdings-Inc.-Updates-2023-Full-Year-Earnings-Guidance/default.aspx)  
 7 [details/2023/Altria-Completes-Acquisition-of-NJOY-Holdings-Inc.-Updates-2023-Full-](https://investor.altria.com/press-releases/news-details/2023/Altria-Completes-Acquisition-of-NJOY-Holdings-Inc.-Updates-2023-Full-Year-Earnings-Guidance/default.aspx)  
 8 [Year-Earnings-Guidance/default.aspx](https://investor.altria.com/press-releases/news-details/2023/Altria-Completes-Acquisition-of-NJOY-Holdings-Inc.-Updates-2023-Full-Year-Earnings-Guidance/default.aspx).

9 27. On information and belief, NJOY Holdings, Inc. is a corporation organized  
 10 under the laws of Delaware, with its principal place of business located at 9449 N. 90th  
 11 Street, Suite 201, Scottsdale, Arizona 85258. On information and belief, NJOY Holdings,  
 12 Inc. is the holding company for NJOY, LLC, the operating company. On information and  
 13 belief, NJOY Holdings, Inc. was acquired by Altria Group, Inc. on June 1, 2023, and is  
 14 now a wholly owned subsidiary of Altria Group, Inc. See [https://investor.altria.com/press-](https://investor.altria.com/press-releases/news-details/2023/Altria-Completes-Acquisition-of-NJOY-Holdings-Inc.-Updates-2023-Full-Year-Earnings-Guidance/default.aspx)  
 15 [releases/news-details/2023/Altria-Completes-Acquisition-of-NJOY-Holdings-Inc.-](https://investor.altria.com/press-releases/news-details/2023/Altria-Completes-Acquisition-of-NJOY-Holdings-Inc.-Updates-2023-Full-Year-Earnings-Guidance/default.aspx)  
 16 [Updates-2023-Full-Year-Earnings-Guidance/default.aspx](https://investor.altria.com/press-releases/news-details/2023/Altria-Completes-Acquisition-of-NJOY-Holdings-Inc.-Updates-2023-Full-Year-Earnings-Guidance/default.aspx).

17 28. On information and belief, Altria Group, Inc. is a corporation organized  
 18 under the laws of the Commonwealth of Virginia, with its principal place of business  
 19 located at 6601 West Broad Street, Richmond, Virginia 23230.

20 29. On information and belief, Altria Group Distribution Company is a  
 21 corporation organized under the laws of the Commonwealth of Virginia, with its principal  
 22 place of business located at 6601 West Broad Street, Richmond, Virginia 23230. On  
 23 information and belief, Altria Group Distribution Company is a wholly owned subsidiary  
 24 of Altria Group, Inc., and provides sales and distribution services to Altria Group, Inc.'s  
 25 operating subsidiaries, such as NJOY. See [https://investor.altria.com/press-releases/news-](https://investor.altria.com/press-releases/news-details/2023/Altria-Completes-Acquisition-of-NJOY-Holdings-Inc.-Updates-2023-Full-Year-Earnings-Guidance/default.aspx)  
 26 [details/2023/Altria-Completes-Acquisition-of-NJOY-Holdings-Inc.-Updates-2023-Full-](https://investor.altria.com/press-releases/news-details/2023/Altria-Completes-Acquisition-of-NJOY-Holdings-Inc.-Updates-2023-Full-Year-Earnings-Guidance/default.aspx)

1 [Year-Earnings-Guidance/default.aspx](#) (“NJOY's products will be distributed by Altria  
2 Group Distribution Company.”).

3 30. On information and belief, Altria Client Services LLC is a limited liability  
4 company organized under the laws of the Commonwealth of Virginia, with its principal  
5 place of business located at 6601 West Broad Street, Richmond, Virginia 23230. On  
6 information and belief, Altria Client Services LLC is a wholly owned subsidiary of Altria  
7 Group, Inc.

8 31. As set forth below, on information and belief, Defendants use in the United  
9 States, import into the United States, sell for importation into the United States, and/or  
10 offer to sell and sell within the United States after importation vaporizer devices, cartridges  
11 used therewith, and components thereof that infringe the Asserted Patents.

#### 12 **IV. JURISDICTION AND VENUE**

13 32. This Court has jurisdiction over the subject matter of this action under 28  
14 U.S.C. §§ 1331 and 1338(a).

15 33. Venue is proper in this district with respect to Defendants under 28 U.S.C. §  
16 1391 and 28 U.S.C. § 1400(b). On information and belief, Defendants have committed  
17 acts of infringement in this District, directly and/or through intermediaries, by, among other  
18 things, making, using, offering to sell, selling, and/or importing products and/or services  
19 that infringe the Asserted Patents, as alleged herein. On information and belief, Defendants  
20 have a regular and established place of business in this District. On information and belief,  
21 NJOY is headquartered in Arizona. On information and belief, Altria employs numerous  
22 sales and account managers based in Arizona, and Altria Group Distribution Company has  
23 a registered agent located in Phoenix, Arizona. On information and belief, NJOY was  
24 acquired by Altria Group, Inc. on June 1, 2023, and is now a wholly owned subsidiary of  
25 Altria Group, Inc. See <https://investor.altria.com/press-releases/news-details/2023/Altria->  
26

1 [Completes-Acquisition-of-NJOY-Holdings-Inc.-Updates-2023-Full-Year-Earnings-](#)  
2 [Guidance/default.aspx.](#)

3       34. This Court has personal jurisdiction over Defendants. On information and  
4 belief, Defendants have conducted and continue to conduct business in the State of Arizona  
5 and this District. Further, Defendants, directly and/or through subsidiaries and/or  
6 intermediaries (including distributors, retailers, franchisees, and others), have committed  
7 and continue to commit acts of patent infringement and/or have contributed to or induced  
8 acts of patent infringement by others in this District and elsewhere in the United States. As  
9 such, Defendants have purposefully availed themselves of the privilege of conducting  
10 business within this District; have established sufficient minimum contacts with this  
11 District such that they should reasonably and fairly anticipate being haled into court in this  
12 District; and have purposefully directed activities at residents of this State. At least a  
13 portion of the patent infringement claims alleged herein arise out of or are related to one or  
14 more of the foregoing activities.

15 **V. THE TECHNOLOGY AND PRODUCTS AT ISSUE**

16 **A. Background of the Technology**

17       35. The technology at issue generally relates to the design and operation of  
18 vaporizer devices, such as ENDS devices, and cartridges used therewith.

19       36. ENDS products generally vaporize a liquid solution containing nicotine (also  
20 called e-liquid) and permit the user to inhale recondensed droplets of that solution as an  
21 aerosol. An e-liquid based ENDS product typically includes a storage compartment that  
22 holds the liquid nicotine solution, a heating element that vaporizes the liquid to generate  
23 an aerosol, and a battery and circuitry to power and operate the heating element.

1           **B.     Products at Issue**

2           37.     The Accused Products are vaporizer devices (such as ENDS devices),  
3 cartridges used therewith, and components thereof (*e.g.*, cartridge housings, atomizers,  
4 atomizer subassemblies, device subassemblies, etc.).

5           **VI.    THE ASSERTED PATENTS AND NON-TECHNICAL DESCRIPTIONS OF**  
6           **THE INVENTIONS<sup>6</sup>**

7           38.     JLI asserts five patents in this Complaint: U.S. Patent No. RE49114 (“the  
8 RE49114 patent”); U.S. Patent No. 10,130,123 (“the ’123 patent”); U.S. Patent No.  
9 10,709,173 (“the ’173 patent”); U.S. Patent No. 11,134,722 (“the ’722 patent”); and U.S.  
10 Patent No. 11,606,981 (“the ’981 patent”). These patents are briefly discussed below.

11           **A.     The RE49114 Patent**

12                   **1.     Identification and Ownership of the RE49114 Patent**

13           39.     U.S. Patent No. RE49114 was duly and lawfully reissued by the United  
14 States Patent and Trademark Office on June 28, 2022 to JUUL Labs, Inc.

15           40.     The RE49114 patent is titled “Electronic Cigarette With Liquid Reservoir,”  
16 names Kyle D. Newton as the sole inventor, and issued from U.S. Patent Application No.  
17 16/359,938, which was filed on March 20, 2019.

18           41.     JUUL Labs, Inc. is the sole owner by assignment of all right, title, and  
19 ownership interest in the RE49114 Patent.

20           42.     A true and correct copy of the RE49114 patent is attached as Exhibit 1.

21  
22 \_\_\_\_\_  
23 <sup>6</sup> All non-technical descriptions of the patents herein are presented to give a general  
24 background of those patents. These statements are not intended to be used nor should they  
25 be used for purposes of patent claim construction. JLI presents these statements subject to  
26 and without waiver of its right to argue that no claim construction is necessary, or that  
claim terms should be construed in a particular way under claim interpretation  
jurisprudence and the relevant evidence.

1                   **2.     Non-Technical Description of the RE49114 Patent**

2           43.     The RE49114 patent describes an electronic cigarette cartridge apparatus that  
3 includes, for example, a mouthpiece having an aerosol outlet, a liquid reservoir (storing a  
4 liquid), an atomizing chamber, and an atomizer. The atomizer selectively generates an  
5 aerosol of the liquid, with the liquid reservoir sealably separated from the atomizing  
6 chamber, in response to electric current flowing through the atomizer. The wick is in  
7 contact with the liquid in the liquid reservoir through wick apertures, and transfers the  
8 liquid by capillarity from the liquid reservoir to the atomizer.

9                   **B.     The '123 Patent**

10                   **1.     Identification and Ownership of the '123 Patent**

11           44.     U.S. Patent No. 10,130,123 was duly and lawfully issued by the United States  
12 Patent and Trademark Office on November 20, 2018 to JUUL Labs, Inc.

13           45.     The '123 patent is titled "Vaporizer Devices With Blow Discrimination";  
14 names Nicholas Jay Hatton and Steven Christensen as co-inventors; and issued from U.S.  
15 Patent Application No. 15/430,317, which was filed on February 10, 2017.

16           46.     JUUL Labs, Inc. is the sole owner by assignment of all right, title, and  
17 ownership interest in the '123 Patent.

18           47.     A true and correct copy of the '123 patent is attached as Exhibit 2.

19                   **2.     Non-Technical Description of the '123 Patent**

20           48.     The '123 patent describes vaporizer devices, such as ENDS devices,  
21 including for example a pressure sensor, a gasket, and a cartridge receptacle for insertably  
22 receiving a cartridge containing vaporizable material. The pressure sensor can include a  
23 first side exposed to a sealed air flow path and a second side exposed to a device air path  
24 open to ambient pressure. The sealed air flow path can include a channel formed between  
25 surfaces of the cartridge and the cartridge receptacle, and pass from an air inlet, through  
26 the channel and to a heater and outlet of the cartridge. The gasket can be included around

1 the pressure sensor to seal the device air path from the sealed air flow path.

2 **C. The '173 Patent**

3 **1. Identification and Ownership of the '173 Patent**

4 49. U.S. Patent No. 10,709,173 was duly and lawfully issued by the United States  
5 Patent and Trademark Office on July 14, 2020 to JUUL Labs, Inc.

6 50. The '173 patent is titled "Vaporizer Apparatus"; names James Monsees,  
7 Adam Bowen, Steven Christensen, Joshua Morenstein, and Christopher Nicholas  
8 HibmaCronan as co-inventors; and issued from U.S. Patent Application No. 16/032,009,  
9 which was filed on July 10, 2018.

10 51. JUUL Labs, Inc. is the sole owner by assignment of all right, title, and  
11 ownership interest in the '173 Patent.

12 52. A true and correct copy of the '173 patent is attached as Exhibit 3.

13 **2. Non-Technical Description of the '173 Patent**

14 53. The '173 patent describes vaporizer apparatuses, such as ENDS. For  
15 example, the patent describes a vaporizer apparatus with a cartridge and a body. The  
16 cartridge can comprise a mouthpiece, a storage compartment, and a heater chamber with a  
17 resistive heating element configured to generate an aerosol comprising vaporizable  
18 material and air passing along an airflow path. The body can comprise a receptacle  
19 configured to insertably receive the cartridge with the heater chamber disposed within the  
20 receptacle. The airflow path can comprise an air inlet passage and a fluid connection in  
21 the cartridge, connecting the heater chamber and the mouthpiece. The air inlet passage can  
22 have, for example, a first side formed by an exterior surface of the cartridge and a second  
23 side formed by an internal surface of the receptacle when the receptacle insertably receives  
24 the cartridge.



1           **D.     The '722 Patent**

2                   **1.     Identification and Ownership of the '722 Patent**

3           54.     U.S. Patent No. 11,134,722 was duly and lawfully issued by the United States  
4 Patent and Trademark Office on October 5, 2021 to VMR Products LLC.

5           55.     The '722 patent is titled "Vaporizer"; names Jan Andries Verleur, Dan Recio,  
6 Yifeng Lu, Yinjun Zhang, Arturo Fajardo, and Hans Verleur as co-inventors; and issued  
7 from U.S. Patent Application No. 16/119,359, which was filed on August 31, 2018.

8           56.     VMR Products LLC is the sole owner by assignment of all right, title, and  
9 ownership interest in the '722 Patent.

10          57.     A true and correct copy of the '722 patent is attached as Exhibit 4.

11                   **2.     Non-Technical Description of the '722 Patent**

12          58.     The '722 patent describes vaporizers, such as an ENDS, that, for example,  
13 have a battery portion that includes a cartomizer receiving segment, a battery housing  
14 segment, and charger electrical contacts, with an outer shell of the battery portion  
15 commonly shared by the battery housing segment and cartomizer receiving segment. An  
16 insertion end of a chamber in the cartomizer receiving segment, which is configured to  
17 receive an inserted cartomizer, is at an opposite end of the battery portion from the charger  
18 electrical contacts. A cartomizer configured for insertion into the chamber includes a  
19 structure for holding a vaporizable liquid, as well as wicking and heating elements.

20           **E.     The '981 Patent**

21                   **1.     Identification and Ownership of the '981 Patent**

22          59.     U.S. Patent No. 11,606,981 was duly and lawfully issued by the United States  
23 Patent and Trademark Office on March 21, 2023 to VMR Products LLC.

24          60.     The '981 patent is titled "Vaporizer"; names Jan Andries Verleur, Dan Recio,  
25 Yifeng Lu, Yinjun Zhang, Arturo Fajardo, and Hans Verleur as co-inventors; and issued  
26 from U.S. Patent Application No. 17/095,567, which was filed on November 11, 2020.

61. VMR Products LLC is the sole owner by assignment of all right, title, and ownership interest in the '981 Patent.

62. A true and correct copy of the '981 patent is attached as Exhibit 5.

## **2. Non-Technical Description of the '981 Patent**

63. The '981 patent describes vaporizers, such as ENDS, that, for example, include a battery portion having a chamber and a cartomizer having a mouthpiece end and an insertion end disposed opposite the mouthpiece end. The cartomizer can include, for example, a cartomizer body having a volume holding a fluid vaporizable substance, with at least a portion of the cartomizer body including a material that allows viewing of the fluid vaporizable substance; a heating element and a wicking element within the cartomizer body; an inhalation tube in fluid communication with the heating element and the wicking element; a mouthpiece at or proximate to the mouthpiece end and in fluid communication with the inhalation tube; and a plurality of cartomizer electrical contacts on an exterior of the insertion end. The plurality of cartomizer electrical contacts is positioned to contact a plurality of battery electrical contacts at a base end of the chamber when the cartomizer body is inserted into the chamber.

## **VII. DEFENDANTS' INFRINGEMENT OF THE ASSERTED PATENTS**

64. As discussed above, the Accused Products are certain vaporizer devices, cartridges used therewith, and components thereof that infringe one or more claims of the Asserted Patents.

65. All conditions precedent to JLI's right to recover have been performed, waived, or otherwise satisfied.

### **A. COUNT I – Infringement of U.S. Patent No. RE49114**

66. JLI hereby incorporates the allegations of the foregoing paragraphs as fully set forth herein.

1           67. Upon information and belief, Defendants have infringed and continue to  
2 directly infringe, either literally or under the doctrine of equivalents, at least claims 1, 5-7,  
3 29, 30, 36, 43, 44, 76, 77, 80, 81, 86, 89, and 93 of the RE49114 patent by making, using,  
4 selling, offering for sale in, and/or importing into the United States Accused Products, such  
5 as the NJOY ACE Device and ACE Pods (collectively “ACE System”).

6           68. An exemplary claim chart comparing independent claims 1, 43, and 44 of the  
7 RE49114 patent to a representative Accused Product (the NJOY ACE System) is attached  
8 as Exhibit 6.

9           69. On information and belief, Defendants also indirectly infringe the RE49114  
10 patent by inducing and/or contributing to infringement. On information and belief,  
11 Defendants have had actual knowledge of the RE49114 patent, including through at least  
12 the filing of JLI’s action in the International Trade Commission alleging infringement of  
13 the Asserted Patents against Defendants, and also have actual knowledge through the filing  
14 of this Complaint.

15           70. On information and belief, Defendants induce infringement of the RE49114  
16 patent under 35 U.S.C. § 271(b) by knowingly and intentionally inducing others to directly  
17 infringe, literally or under the doctrine of equivalents, the RE49114 patent. On information  
18 and belief, the Accused Products are specially designed to contain features that infringe the  
19 RE49114 patent, and the Accused Products have no substantial uses other than ones that  
20 infringe the RE49114 patent. For example, on information and belief, Defendants sell the  
21 accused ACE Device and the accused ACE Pods separately, but provide instructions with  
22 both the ACE Device and ACE Pods explaining how to use the system by placing the pods  
23 into the device. On information and belief, Defendants also actively promote the sale, use,  
24 and importation of the Accused Products in marketing materials, technical specifications,  
25 data sheets, webpages, press releases, and user manuals, as well as through their sales and  
26 distribution channels that encourage infringing sales, offers to sell, and importation of the

1 Accused Products. Through these actions, Defendants have had the specific intent to  
2 induce, or were willfully blind to inducing infringement of the RE49114 patent. On  
3 information and belief, Defendants continue to engage in these activities with knowledge  
4 of the RE49114 patent and knowledge that the induced acts constitute infringement.

5 71. On information and belief, Defendants also contribute to infringement of the  
6 RE49114 patent under 35 U.S.C. § 271(c) by providing or selling the Accused Products  
7 (even if separately sold as the ACE Device and ACE Pods) to others. The Accused  
8 Products are specially designed and made for use in an infringing manner and are not staple  
9 articles of commerce suitable for any substantial non-infringing use. On information and  
10 belief, Defendants continue to engage in these activities with knowledge of the RE49114  
11 patent and knowledge that their acts contribute to infringement.

12 72. On information and belief, Defendants' infringement is willful. For example,  
13 on information and belief, Defendants have been on notice of the RE49114 patent and their  
14 infringement of it since at least the filing of JLI's action in the International Trade  
15 Commission alleging infringement of the Asserted Patents against Defendants, as well as  
16 the filing of this Complaint, but continue their infringing activities.

17 73. JLI has suffered, and will continue to suffer, irreparable harm as a result of  
18 Defendants' infringement of the RE49114 patent for which there is no adequate remedy at  
19 law, unless Defendants' infringement is enjoined by this Court. Accordingly, JLI seeks a  
20 permanent injunction enjoining Defendants from making, using, selling, offering to sell,  
21 and/or importing the Accused Products, and/or otherwise infringing, or inducing or  
22 contributing to the infringement of, the RE49114 patent.

23 **B. COUNT II – Infringement of U.S. Patent No. 10,130,123**

24 74. JLI hereby incorporates the allegations of the foregoing paragraphs as fully  
25 set forth herein.

26 75. Upon information and belief, Defendants have infringed and continue to

1 directly infringe, either literally or under the doctrine of equivalents, at least claims 14, 16,  
2 18, 27, 29, 31, and 32 of the '123 patent by making, using, selling, offering for sale in,  
3 and/or importing into the United States Accused Products, such as the NJOY ACE Device  
4 and ACE Pods.

5 76. An exemplary claim chart comparing independent claims 14 and 27 of the  
6 '123 patent to a representative Accused Product (the NJOY ACE System) is attached as  
7 Exhibit 7.

8 77. On information and belief, Defendants also indirectly infringe the '123 patent  
9 by inducing and/or contributing to infringement. On information and belief, Defendants  
10 have had actual knowledge of the '123 patent, including through at least the filing of JLI's  
11 action in the International Trade Commission alleging infringement of the Asserted Patents  
12 against Defendants, and also have actual knowledge through the filing of this Complaint.

13 78. On information and belief, Defendants induce infringement of the '123  
14 patent under 35 U.S.C. § 271(b) by knowingly and intentionally inducing others to directly  
15 infringe, literally or under the doctrine of equivalents, the '123 patent. On information and  
16 belief, the Accused Products are specially designed to contain features that infringe the  
17 '123 patent, and the Accused Products have no substantial uses other than ones that infringe  
18 the '123 patent. For example, on information and belief, Defendants sell the accused ACE  
19 Device and the accused ACE Pods separately, but provide instructions with both the ACE  
20 Device and ACE Pods explaining how to use the system by placing the pods into the device.  
21 On information and belief, Defendants also actively promote the sale, use, and importation  
22 of the Accused Products in marketing materials, technical specifications, data sheets,  
23 webpages, press releases, and user manuals, as well as through their sales and distribution  
24 channels that encourage infringing sales, offers to sell, and importation of the Accused  
25 Products. Through these actions, Defendants have had the specific intent to induce, or  
26 were willfully blind to inducing infringement of the '123 patent. On information and

1 belief, Defendants continue to engage in these activities with knowledge of the '123 patent  
2 and knowledge that the induced acts constitute infringement.

3 79. On information and belief, Defendants also contribute to infringement of the  
4 '123 patent under 35 U.S.C. § 271(c) by providing or selling the Accused Products (even  
5 if separately sold as the ACE Device and ACE Pods) to others. The Accused Products are  
6 specially designed and made for use in an infringing manner and are not staple articles of  
7 commerce suitable for any substantial non-infringing use. On information and belief,  
8 Defendants continue to engage in these activities with knowledge of the '123 patent and  
9 knowledge that their acts contribute to infringement.

10 80. On information and belief, Defendants' infringement is willful. For example,  
11 on information and belief, Defendants have been on notice of the '123 patent and their  
12 infringement of it since at least the filing of JLI's action in the International Trade  
13 Commission alleging infringement of the Asserted Patents against Defendants, as well as  
14 the filing of this Complaint, but continue their infringing activities.

15 81. JLI has suffered, and will continue to suffer, irreparable harm as a result of  
16 Defendants' infringement of the '123 patent for which there is no adequate remedy at law,  
17 unless Defendants' infringement is enjoined by this Court. Accordingly, JLI seeks a  
18 permanent injunction enjoining Defendants from making, using, selling, offering to sell,  
19 and/or importing the Accused Products, and/or otherwise infringing, or inducing or  
20 contributing to the infringement of, the '123 patent.

21 **C. COUNT III – Infringement of U.S. Patent No. 10,709,173**

22 82. JLI hereby incorporates the allegations of the foregoing paragraphs as fully  
23 set forth herein.

24 83. Upon information and belief, Defendants have infringed and continue to  
25 directly infringe, either literally or under the doctrine of equivalents, at least claims 1, 2-4,  
26 6-7, 15, 16, 18, 19, 20, 21-25, 28, and 30 of the '173 patent by making, using, selling,

1 offering for sale in, and/or importing into the United States Accused Products, such as the  
2 NJOY ACE Device and ACE Pods.

3 84. An exemplary claim chart comparing independent claims 1 and 20 of the  
4 '173 patent to a representative Accused Product (the NJOY ACE System) is attached as  
5 Exhibit 8.

6 85. On information and belief, Defendants also indirectly infringe the '173 patent  
7 by inducing and/or contributing to infringement. On information and belief, Defendants  
8 have had actual knowledge of the '173 patent, including through at least the filing of JLI's  
9 action in the International Trade Commission alleging infringement of the Asserted Patents  
10 against Defendants, and also have actual knowledge through the filing of this Complaint.

11 86. On information and belief, Defendants induce infringement of the '173  
12 patent under 35 U.S.C. § 271(b) by knowingly and intentionally inducing others to directly  
13 infringe, literally or under the doctrine of equivalents, the '173 patent. On information and  
14 belief, the Accused Products are specially designed to contain features that infringe the  
15 '173 patent, and the Accused Products have no substantial uses other than ones that infringe  
16 the '173 patent. For example, on information and belief, Defendants sell the accused ACE  
17 Device and the accused ACE Pods separately, but provide instructions with both the ACE  
18 Device and ACE Pods explaining how to use the system by placing the pods into the device.  
19 On information and belief, Defendants also actively promote the sale, use, and importation  
20 of the Accused Products in marketing materials, technical specifications, data sheets,  
21 webpages, press releases, and user manuals, as well as through their sales and distribution  
22 channels that encourage infringing sales, offers to sell, and importation of the Accused  
23 Products. Through these actions, Defendants have had the specific intent to induce, or  
24 were willfully blind to inducing infringement of the '173 patent. On information and  
25 belief, Defendants continue to engage in these activities with knowledge of the '173 patent  
26 and knowledge that the induced acts constitute infringement.

1           87. On information and belief, Defendants also contribute to infringement of the  
2 '173 patent under 35 U.S.C. § 271(c) by providing or selling the Accused Products (even  
3 if separately sold as the ACE Device and ACE Pods) to others. The Accused Products are  
4 specially designed and made for use in an infringing manner and are not staple articles of  
5 commerce suitable for any substantial non-infringing use. On information and belief,  
6 Defendants continue to engage in these activities with knowledge of the '173 patent and  
7 knowledge that their acts contribute to infringement.

8           88. On information and belief, Defendants' infringement is willful. For example,  
9 on information and belief, Defendants have been on notice of the '173 patent and their  
10 infringement of it since at least the filing of JLI's action in the International Trade  
11 Commission alleging infringement of the Asserted Patents against Defendants, as well as  
12 the filing of this Complaint, but continue their infringing activities.

13           89. JLI has suffered, and will continue to suffer, irreparable harm as a result of  
14 Defendants' infringement of the '173 patent for which there is no adequate remedy at law,  
15 unless Defendants' infringement is enjoined by this Court. Accordingly, JLI seeks a  
16 permanent injunction enjoining Defendants from making, using, selling, offering to sell,  
17 and/or importing the Accused Products, and/or otherwise infringing, or inducing or  
18 contributing to the infringement of, the '173 patent.

19           **D. COUNT IV – Infringement of U.S. Patent No. 11,134,722**

20           90. JLI hereby incorporates the allegations of the foregoing paragraphs as fully  
21 set forth herein.

22           91. Upon information and belief, Defendants have infringed and continue to  
23 directly infringe, either literally or under the doctrine of equivalents, at least claims 1, 3, 5,  
24 7-9, 10, 11-14, 15, and 16-21 of the '722 patent by making, using, selling, offering for sale  
25 in, and/or importing into the United States Accused Products, such as the NJOY ACE  
26 Device and ACE Pods.



1           92. An exemplary claim chart comparing independent claims 1, 10, and 15 of the  
2 '722 patent to a representative Accused Product (the NJOY ACE System) is attached as  
3 Exhibit 9.

4           93. On information and belief, Defendants also indirectly infringe the '722 patent  
5 by inducing and/or contributing to infringement. On information and belief, Defendants  
6 have had actual knowledge of the '722 patent, including through at least the filing of JLI's  
7 action in the International Trade Commission alleging infringement of the Asserted Patents  
8 against Defendants, and also have actual knowledge through the filing of this Complaint.

9           94. On information and belief, Defendants induce infringement of the '722  
10 patent under 35 U.S.C. § 271(b) by knowingly and intentionally inducing others to directly  
11 infringe, literally or under the doctrine of equivalents, the '722 patent. On information and  
12 belief, the Accused Products are specially designed to contain features that infringe the  
13 '722 patent, and the Accused Products have no substantial uses other than ones that infringe  
14 the '722 patent. For example, on information and belief, Defendants sell the accused ACE  
15 Device and the accused ACE Pods separately, but provide instructions with both the ACE  
16 Device and ACE Pods explaining how to use the system by placing the pods into the device.  
17 On information and belief, Defendants also actively promote the sale, use, and importation  
18 of the Accused Products in marketing materials, technical specifications, data sheets,  
19 webpages, press releases, and user manuals, as well as through their sales and distribution  
20 channels that encourage infringing sales, offers to sell, and importation of the Accused  
21 Products. Through these actions, Defendants have had the specific intent to induce, or  
22 were willfully blind to inducing infringement of the '722 patent. On information and  
23 belief, Defendants continue to engage in these activities with knowledge of the '722 patent  
24 and knowledge that the induced acts constitute infringement.

25           95. On information and belief, Defendants also contribute to infringement of the  
26 '722 patent under 35 U.S.C. § 271(c) by providing or selling the Accused Products (even

1 if separately sold as the ACE Device and ACE Pods) to others. The Accused Products are  
2 specially designed and made for use in an infringing manner and are not staple articles of  
3 commerce suitable for any substantial non-infringing use. On information and belief,  
4 Defendants continue to engage in these activities with knowledge of the '722 patent and  
5 knowledge that their acts contribute to infringement.

6 96. On information and belief, Defendants' infringement is willful. For example,  
7 on information and belief, Defendants have been on notice of the '722 patent and their  
8 infringement of it since at least the filing of JLI's action in the International Trade  
9 Commission alleging infringement of the Asserted Patents against Defendants, as well as  
10 the filing of this Complaint, but continue their infringing activities.

11 97. JLI has suffered, and will continue to suffer, irreparable harm as a result of  
12 Defendants' infringement of the '722 patent for which there is no adequate remedy at law,  
13 unless Defendants' infringement is enjoined by this Court. Accordingly, JLI seeks a  
14 permanent injunction enjoining Defendants from making, using, selling, offering to sell,  
15 and/or importing the Accused Products, and/or otherwise infringing, or inducing or  
16 contributing to the infringement of, the '722 patent.

17 **E. COUNT V – Infringement of U.S. Patent No. 11,606,981**

18 98. JLI hereby incorporates the allegations of the foregoing paragraphs as fully  
19 set forth herein.

20 99. Upon information and belief, Defendants have infringed and continue to  
21 directly infringe, either literally or under the doctrine of equivalents, at least claims 1, 2, 5,  
22 6, 8, 9, 10, 11, 13, 14-16, 17, and 18 of the '981 patent by making, using, selling, offering  
23 for sale in, and/or importing into the United States Accused Products, such as the NJOY  
24 ACE Device and ACE Pods.

1           100. An exemplary claim chart comparing independent claims 1, 9, 13, and 17 of  
2 the '981 patent to a representative Accused Product (the NJOY ACE System) is attached  
3 as Exhibit 10.

4           101. On information and belief, Defendants also indirectly infringe the '981 patent  
5 by inducing and/or contributing to infringement. On information and belief, Defendants  
6 have had actual knowledge of the '981 patent, including through at least the filing of JLI's  
7 action in the International Trade Commission alleging infringement of the Asserted Patents  
8 against Defendants, and also have actual knowledge through the filing of this Complaint.

9           102. On information and belief, Defendants induce infringement of the '981  
10 patent under 35 U.S.C. § 271(b) by knowingly and intentionally inducing others to directly  
11 infringe, literally or under the doctrine of equivalents, the '981 patent. On information and  
12 belief, the Accused Products are specially designed to contain features that infringe the  
13 '981 patent, and the Accused Products have no substantial uses other than ones that infringe  
14 the '981 patent. For example, on information and belief, Defendants sell the accused ACE  
15 Device and the accused ACE Pods separately, but provide instructions with both the ACE  
16 Device and ACE Pods explaining how to use the system by placing the pods into the device.  
17 On information and belief, Defendants also actively promote the sale, use, and importation  
18 of the Accused Products in marketing materials, technical specifications, data sheets,  
19 webpages, press releases, and user manuals, as well as through their sales and distribution  
20 channels that encourage infringing sales, offers to sell, and importation of the Accused  
21 Products. Through these actions, Defendants have had the specific intent to induce, or  
22 were willfully blind to inducing infringement of the '981 patent. On information and  
23 belief, Defendants continue to engage in these activities with knowledge of the '981 patent  
24 and knowledge that the induced acts constitute infringement.

25           103. On information and belief, Defendants also contribute to infringement of the  
26 '981 patent under 35 U.S.C. § 271(c) by providing or selling the Accused Products (even

1 if separately sold as the ACE Device and ACE Pods) to others. The Accused Products are  
2 specially designed and made for use in an infringing manner and are not staple articles of  
3 commerce suitable for any substantial non-infringing use. On information and belief,  
4 Defendants continue to engage in these activities with knowledge of the '981 patent and  
5 knowledge that their acts contribute to infringement.

6 104. On information and belief, Defendants' infringement is willful. For example,  
7 on information and belief, Defendants have been on notice of the '981 patent and their  
8 infringement of it since at least the filing of JLI's action in the International Trade  
9 Commission alleging infringement of the Asserted Patents against Defendants, as well as  
10 the filing of this Complaint, but continue their infringing activities.

11 105. JLI has suffered, and will continue to suffer, irreparable harm as a result of  
12 Defendants' infringement of the '981 patent for which there is no adequate remedy at law,  
13 unless Defendants' infringement is enjoined by this Court. Accordingly, JLI seeks a  
14 permanent injunction enjoining Defendants from making, using, selling, offering to sell,  
15 and/or importing the Accused Products, and/or otherwise infringing, or inducing or  
16 contributing to the infringement of, the '981 patent.

#### 17 **VIII. DEMAND FOR JURY TRIAL**

18 Pursuant to Rule 38 of the Federal Rules of Civil Procedure, Plaintiffs hereby  
19 demand a trial by jury as to all issues so triable.

#### 20 **IX. PRAYER FOR RELIEF**

21 WHEREFORE, Plaintiffs respectfully pray for the following relief:

22 (a) A judgment that Defendants have infringed each and every one of the  
23 Asserted Patents;

24 (b) A judgment that Defendants' infringement of each and every one of the  
25 Asserted Patents is willful;

26 (c) Damages adequate to compensate JLI for the Defendants' infringement of

1 the Asserted Patents pursuant to 35 U.S.C. § 284;

2 (d) Entry of a permanent injunction enjoining Defendants from making, using,  
3 selling, offering to sell, and/or importing the Accused Products, and/or otherwise  
4 infringing, or inducing or contributing to the infringement of, any of the Asserted Patents;

5 (e) Pre-judgment interest;

6 (f) Post-judgment interest;

7 (g) A declaration that this action is exceptional pursuant to 35 U.S.C. § 285, and  
8 an award to JLI of its attorneys' fees, costs, and expenses incurred in connection with this  
9 action; and

10 (h) Such other relief as the Court deems just and equitable.

11 RESPECTFULLY SUBMITTED: June 30, 2023.

12 **COPPERSMITH BROCKELMAN PLC**

13  
14 /s/ Nathan J. Kunz

15 Nathan J. Kunz

16 Malvika A. Sinha

17 **QUINN EMANUEL URQUHART & SULLIVAN, LLP**

18 Kevin P.B. Johnson (*pro hac vice forthcoming*)

19 Victoria F. Maroulis (*pro hac vice forthcoming*)

20  
21 S. Alex Lasher (*pro hac vice forthcoming*)

22 K. Kevin Chu (*pro hac vice forthcoming*)

23 1300 I Street, NW, Suite 900

24 Washington, D.C. 20005

25 Tel.: (202) 538-8000

26 [alexlasher@quinnemanuel.com](mailto:alexlasher@quinnemanuel.com)

[kevinchu@quinnemanuel.com](mailto:kevinchu@quinnemanuel.com)

1 Andrew M. Holmes (*pro hac vice forthcoming*)  
2 Iman Lordgooei (*pro hac vice forthcoming*)  
3 50 California Street, 22nd Floor  
4 San Francisco, CA 94111  
5 Tel.: (415) 875-6600  
6 [drewholmes@quinnemanuel.com](mailto:drewholmes@quinnemanuel.com)  
7 [imanlordgooei@quinnemanuel.com](mailto:imanlordgooei@quinnemanuel.com)

8 **MINTZ LEVIN COHN FERRIS GLOVSKY**  
9 **AND POPEO P.C.**

10 Michael T. Renaud (*pro hac vice forthcoming*)

11 One Financial Center  
12 Boston, MA 02111  
13 Tel: (617) 542-6000  
14 [MTRenaud@mintz.com](mailto:MTRenaud@mintz.com)

15 Jonathan J. Engler (*pro hac vice forthcoming*)  
16 555 12th Street NW, Suite 1100  
17 Washington, D.C. 20004  
18 Tel: (202) 434-7446  
19 [JJEngler@mintz.com](mailto:JJEngler@mintz.com)

20 *Attorneys for Plaintiffs,*  
21 *JUUL Labs, Inc. and VMR Products LLC*  
22  
23  
24  
25  
26